Overview
Actinic keratoses (AKs) are precancerous skin lesions caused by chronic sun exposure, often presenting as scaly, erythematous patches that may progress to squamous cell carcinoma if left untreated 1.Diagnosis
Clinical appearance of scaly, erythematous, or hyperkeratotic lesions 1.
Biopsy for histopathological confirmation if atypical features are present 1.
No specific grading system mentioned in the provided abstracts 1.Management
First-line treatments: Photodynamic therapy (PDT) using methyl aminolaevulinate 1.
Adjunctive considerations: Adjust fluence rate during PDT to manage pain; lower fluence rates (e.g., 34 mW/cm2) may reduce pain compared to higher rates (e.g., 68 mW/cm2) 1.
Pain management: Monitor protoporphyrin IX (PpIX) fluorescence to correlate with pain levels and adjust treatment parameters accordingly 1.Special Populations
No specific guidance: The provided abstracts do not cover management in pregnancy, pediatrics, elderly, or patients with comorbidities 1.Key Recommendations
Adjust fluence rate during photodynamic therapy for actinic keratoses to minimize patient discomfort, considering protoporphyrin IX fluorescence levels 1 (Evidence: Moderate).
Consider lower fluence rates (e.g., 34 mW/cm2) in photodynamic therapy to reduce pain compared to higher rates (e.g., 68 mW/cm2) 1 (Evidence: Moderate).
Monitor protoporphyrin IX fluorescence prior to illumination to better predict and manage pain during photodynamic therapy 1 (Evidence: Moderate).References
1 Wiegell SR, Skiveren J, Philipsen PA, Wulf HC. Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate. The British journal of dermatology 2008. link